In a stark reflection of the challenges facing the biotech sector, 10X Genomics Inc (NASDAQ:TXG) stock has tumbled to a 52-week low, touching down at $11.89. According to InvestingPro data, technical ...

Besides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for.

Group NFM for 2024 at 3.12% is higher by 44bps compared to 2023. Average yield improved by 227bps while average COF also ...

Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the ...

Check the time stamp on this data. Updated AI-Generated Signals for 10x Genomics Inc. (TXG) available here: TXG. Type a few ...

February 07, 2025, 07:36 AM ET, BY Rick W., Contributor | Editor: Derek Curry ( Follow on LinkedIn ) ...

EST Cathie Wood’s ARK Investment buys 250K shares of 10x Genomics (TXG) todayMaximize Your Portfolio with Data Driven Insights:Leverage ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...

Cathie Wood and Ark Invest sold roughly $7,379,804 worth of Palantir stock — and spent $9,145,824 on three biotech stocks.